Psoriasis und Adipositas

Zusammenfassung

Die Psoriasis ist eine chronisch-entzündliche Hauterkrankung. Der Entzündungsprozess betrifft nicht nur die Haut, sondern auch weitere Gewebe, wie Gelenke, Bänder und die Gefäße. Bei einem Großteil aller Psoriasis-Patienten bestehen Nebenerkrankungen wie Diabetes, Übergewicht, Fettstoffwechselstörungen und erhöhter Blutdruck. Der genaue pathophysiologische Zusammenhang zwischen Adipositas und Psoriasis ist nicht hinreichend geklärt. Es ist unklar, ob Psoriasis die Entstehung von Übergewicht begünstigt oder ob Adipositas die Entstehung einer Psoriasis durch einen chronisch pro-inflammatorischen Zustand fördert. Neuere Daten zeigen einen deutlichen Zusammenhang zwischen der Konzentration freier Fettsäuren und dem Ausprägungsgrad der Psoriasis. Eine Ernährungsumstellung und eine erhöhte körperliche Aktivität haben grundsätzlich eine positive Wirkung auf die Schuppenflechte und können das Ansprechen der verschiedenen Therapien erhöhen.

ABSTRACT

Psoriasis is a chronic inflammatory skin disease. The inflammatory process does not only affect the skin, but also other tissues as joints, ligaments and vessels. A majority of patients also suffers from other diseases like diabetes, obesity, alterations of fat metabolism and elevated blood pressure. The pathophysiological association is not sufficiently understood as of yet. There is incertitude if psoriasis promotes obesity or if obesity as a chronic proinflammatory disease promotes psoriasis. Recent data show an association between the concentration of free fatty acids and the severity of psoriasis. Dietary changes and increased physical activities principally have a positive impact on the psoriasis and can improve the therapeutic response.

Schlüsselwörter

Psoriasis - Adipositas - Übergewicht - freie Fettsäuren

Key words

psoriasis - obesity - free fatty acids

Publikationsverlauf

Artikel online veröffentlicht:
29. November 2022

• Literatur

• 1 Greb JE, Goldminz AM, Elder JT. et al. Psoriasis. Nature reviews. Disease primers 2016; 2: 16082
• 2 Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. Journal of the European Academy of Dermatology and Venereology 2012; 26: 3-11
• 3 Griffiths CEM, Armstrong AW, Gudjonsson JE. et al. Psoriasis. Lancet (London, England) 2021; 397: 1301-1315
• 4 Schäkel K. Pathogenese der Psoriasis vulgaris. Der Hautarzt 2016; 6: 1-9
• 5 Schön MP, Boehncke W-H. Psoriasis. The New England journal of medicine 2005; 352: 1899-1912
• 6 Boehncke W-H. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Frontiers in immunology 2018; 9: 579
• 7 Roberson EDO, Bowcock AM. Psoriasis genetics: breaking the barrier. Trends in genetics: TIG 2010; 26: 415-423
• 8 Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: A comprehensive review. Journal of autoimmunity 2015; 64: 66-73
• 9 Zeng J, Luo S, Huang Y. et al. Critical role of environmental factors in the pathogenesis of psoriasis. The Journal of dermatology 2017; 44: 863-872
• 10 Kunz M, Simon JC, Saalbach A. Psoriasis: Obesity and Fatty Acids. Frontiers in immunology 2019; 10: 1807
• 11 Carrascosa JM, Rocamora V, Fernandez-Torres RM. et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas dermo-sifiliograficas 2014; 105: 31-44
• 12 Jensen P, Skov L. Psoriasis and Obesity. Dermatology (Basel, Switzerland) 2016; 232: 633-639
• 13 Nast A, Altenburg A, Augustin M. et al. Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidität. Journal der Deutschen Dermatologischen Gesellschaft=Journal of the German Society of Dermatology 2021; 19: 1092-1117
• 14 Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244
• 15 Puzenat E, Bronsard V, Prey S. et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. Journal of the European Academy of Dermatology and Venereology 2010; 24: 10-16
• 16 Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clinical and experimental dermatology 1994; 19: 210-216
• 17 Mrowietz U, Kragballe K, Reich K. et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of dermatological research 2010; 303: 1-10
• 18 Lebwohl MG, Papp KA, Stein Gold L. et al. Trial of Roflumilast Cream for Chronic Plaque Psoriasis. The. New England journal of medicine 2020; 383: 229-239
• 19 Helliwell PS, Taylor WJ. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs – comparison of drugs and adverse reactions. The Journal of rheumatology 2008; 35: 472-476
• 20 Kumar S, Kachhawha D, Das Koolwal G. et al. Psychiatric morbidity in psoriasis patients: a pilot study. Indian journal of dermatology, venereology and leprology 2011; 77: 625
• 21 Hu SC-S, Lan C-CE. Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment. International journal of molecular sciences 2017; 18: 2211
• 22 Gisterå A, Hansson GK. The immunology of atherosclerosis. Nature reviews. Nephrology 2017; 13: 368-380
• 23 Castaldo G, Pagano I, Grimaldi M. et al. Effect of Very-Low-Calorie Ketogenic Diet on Psoriasis Patients: A Nuclear Magnetic Resonance-Based Metabolomic Study. Journal of proteome research 2021; 20: 1509-1521
• 24 de Arruda LH, De Moraes AP. The impact of psoriasis on quality of life. The British journal of dermatology 2001; 144: 33-36
• 25 Kisielnicka A, Szczerkowska-Dobosz A, Nowicki RJ. The influence of body weight of patients with chronic plaque psoriasis on biological treatment response. Postepy dermatologii i alergologii 2020; 37: 168-173
• 26 Mehta NN, Yu Y, Saboury B. et al. Systemic and Vascular Inflammation in Patients with Moderate to Severe Psoriasis as measured by 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT): A Pilot Study. Archives of dermatology 2011; 147: 1031-1039
• 27 Tan E, Baker C, Foley P. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis. The Australasian journal of dermatology 2013; 54: 259-263
• 28 Gelfand JM, Dommasch ED, Shin DB. et al. The risk of stroke in patients with psoriasis. The Journal of investigative dermatology 2009; 129: 2411-2418
• 29 Parisi R, Rutter MK, Lunt M. et al. Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink. The Journal of investigative dermatology 2015; 135: 2189-2197
• 30 Wakkee M, Herings RMC, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. The Journal of investigative dermatology 2010; 130: 962-967
• 31 de Heredia FP, Gómez-Martínez S, Marcos A. Obesity, inflammation and the immune system. The Proceedings of the Nutrition Society 2012; 71: 332-338
• 32 Carrascosa JM, Rocamora V, Fernandez-Torres RM. et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas dermo-sifiliograficas 2014; 105: 31-44
• 33 Icen M, Crowson CS, McEvoy MT. et al. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. Journal of the American Academy of Dermatology 2009; 60: 394-401
• 34 Naldi L, Chatenoud L, Linder D. et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. The Journal of investigative dermatology 2005; 125: 61-67
• 35 Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Archives of internal medicine 2007; 167: 1670-1675
• 36 Hamminga EA, van der Lely AJ, Neumann HAM. et al. Chronic inflammation in psoriasis and obesity: implications for therapy. Medical hypotheses 2006; 67: 768-773
• 37 Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutrition & diabetes 2012; 2: e54
• 38 Kanda N, Hoashi T, Saeki H. Nutrition and Psoriasis. International journal of molecular sciences 2020; 21: 5405
• 39 Edson-Heredia E, Sterling KL, Alatorre CI. et al. Heterogeneity of response to biologic treatment: perspective for psoriasis. The Journal of investigative dermatology 2014; 134: 18-23
• 40 Ford AR, Siegel M, Bagel J. et al. Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. JAMA dermatology 2018; 154: 934-950
• 41 Alotaibi HA. Effects of Weight Loss on Psoriasis: A Review of Clinical Trials. Cureus 2018; 10: e3491
• 42 Upala S, Sanguankeo A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. International journal of obesity 2005; 2015: 1197-1202
• 43 Castaldo G, Galdo G, Rotondi Aufiero F. et al. Very low-calorie ketogenic diet may allow restoring response to systemic therapy in relapsing plaque psoriasis. Obesity research & clinical practice 2016; 10: 348-352
• 44 Castaldo G, Rastrelli L, Galdo G. et al. Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: A proof-of-concept, single-arm, open-label clinical trial. Nutrition (Burbank, Los Angeles County, Calif.) 2020; 74: 110757
• 45 Rucević I, Perl A, Barisić-Drusko V. et al. The role of the low energy diet in psoriasis vulgaris treatment. Collegium antropologicum 2003; 27: 41-48
• 46 Stelzner K, Herbert D, Popkova Y. et al. Free fatty acids sensitize dendritic cells to amplify TH1/TH17-immune responses. European journal of immunology 2016; 46: 2043-2053
• 47 Herbert D, Franz S, Popkova Y. et al. High-Fat Diet Exacerbates Early Psoriatic Skin Inflammation Independent of Obesity: Saturated Fatty Acids as Key Players. The Journal of investigative dermatology 2018; 138: 1999-2009
• 48 Qin S, Wen J, Bai X-C. et al. Endogenous n-3 polyunsaturated fatty acids protect against imiquimod-induced psoriasis-like inflammation via the IL-17/IL-23 axis. Molecular medicine reports 2014; 9: 2097-2104
• 49 Mari NL. n-3 polyunsaturated fatty acids supplementation in psoriasis: a review. Nutrire 2017; 42: 1-6
• 50 Guida B, Napoleone A, Trio R. et al. Energy-restricted, n-3 polyunsaturated fatty acids-rich diet improves the clinical response to immuno-modulating drugs in obese patients with plaque-type psoriasis: a randomized control clinical trial. Clinical nutrition (Edinburgh, Scotland) 2014; 33: 399-405
• 51 Clark CCT, Taghizadeh M, Nahavandi M. et al. Efficacy of ω-3 supplementation in patients with psoriasis: a meta-analysis of randomized controlled trials. Clinical rheumatology 2019; 38: 977-988
• 52 Barrea L, Balato N, Di Somma C. et al. Nutrition and psoriasis: is there any association between the severity of the disease and adherence to the Mediterranean diet?. Journal of translational medicine 2015; 13: 1-10
• 53 Phan C, Touvier M, Kesse-Guyot E. et al. Association Between Mediterranean Anti-inflammatory Dietary Profile and Severity of Psoriasis: Results From the NutriNet-Santé Cohort. JAMA dermatology 2018; 154: 1017-1024
• 54 Murray ML, Bergstresser PR, Adams-Huet B. et al. Relationship of psoriasis severity to obesity using same-gender siblings as controls for obesity. Clinical and experimental dermatology 2009; 34: 140-144
• 55 Yanaba K, Umezawa Y, Ito T. et al. Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: a retrospective cohort study of 111 patients. Archives of dermatological research 2014; 306: 921-925
• 56 Schwarz PEH, Pinter A, Melzer N. et al. ERAPSO: Revealing the High Burden of Obesity in German Psoriasis Patients. Dermatology and therapy 2019; 9: 579-587